Volume 18, Number 5—May 2012
Letter
Serologic Evidence of West Nile Virus Infection among Humans, Morocco
Hicham El Rhaffouli
, Mehdi El Harrak, Chafiqa Lotfi, Fatima El Boukhrissi, Tahar Bajjou, Abdelilah Laraqui, Farida Hilali, Mouna Kenfaoui, and Idriss Lahlou-Amine
, Mehdi El Harrak, Chafiqa Lotfi, Fatima El Boukhrissi, Tahar Bajjou, Abdelilah Laraqui, Farida Hilali, Mouna Kenfaoui, and Idriss Lahlou-Amine
Table
West Nile virus neutralizing antibody titers in human serum samples obtained during March–April 2011, Morocco
| Cohort, location* | No. samples positive/no. tested (%) | Median ± SD | Titer (%) |
||
|---|---|---|---|---|---|
| Weak, 18–80 | Intermediate, 81–320 | High, >320 | |||
| A, Meknes | 7/150 (4.7) | 54 ± 42.5 | 5 (71.4) | 1 (14.3) | 1 (14.3) |
| B, Rabat | 24/200 (12) | 54 ± 31 | 22 (91.7) | 1 (4.2) | 1 (4.2) |
| C, Kenitra | 28/149 (18.8) | 95 ± 72 | 19 (67.9) | 3 (10.7) | 6 (21.4) |
| Total | 59/499 (11.8) | 72 ± 41 | 46 (78) | 5 (8.5) | 9 (13.5) |
*Study participants were divided into 3 cohorts according to the vicinity from which they were recruited.
Page created: March 16, 2012
Page updated: March 16, 2012
Page reviewed: March 16, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.